
A.
DAUDI
CAL-1
86%
10%
Patient # 1
34%
6%
AV FITC
7AAD
B.
% Viability (FC)
GEN 2.2
CAL-1
Negative control
SL-401 concentrations (fM)
C.
% Viability (FC)
#1
#2
#3
#4
#5
#6
#7
#8
#9
#10
#11
#12
mean
Negative control
SL-401 concentrations (fM)
D.
% Viability (MTT)
Negative control
#4
#3
GEN 2.2
CAL-1
SL-401 concentrations (fM)
E.
% Viability (FC)
Diagnosis
Relapse
SL-401 concentrations (fM)


100
80
60
40
20
0
Viability (%)
No SL-401
SL-401
L-ASP
ASP
MTX
CYC
CYT
DEX
VIN
IDA
Drugs


% Viability
100
80
60
40
20
0
ALL
ALL+SL-401
AML
AML+SL-401
BPDCN
BPDCN+SL-401


A.
NSG survival rate
Percent survival
Days
PBS
SL-401
B.
NSG survival
PBS (n=8)
SL-401 (n=8)
**
Days
C.
SSC
FSC
m CD45
hCD45
BDCA-4
CD4
CD3
CD4
CD56
CD34
D
BPDCN cells /µl
SL-401
no-SL-401
days
E.
Hemoglobin (g/dL)
SL-401
PBS
No treatment
Days
White Blood Cells (x10⁹/L)
SL-401
PBS
No treatment
Days
Platelet (x10⁹/L)